AstraZeneca Collaborates with CSPC
Ticker: AZN · Form: 6-K · Filed: Jun 13, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, drug-development, partnership
Related Tickers: AZN
TL;DR
AZN inks new deal with CSPC to boost drug pipeline.
AI Summary
AstraZeneca PLC announced on June 13, 2025, that it has entered into a collaboration with CSPC. This partnership aims to advance the development of innovative medicines.
Why It Matters
This collaboration could lead to new treatments for patients and expand AstraZeneca's drug development pipeline.
Risk Assessment
Risk Level: low — The filing is an announcement of a collaboration, which is a standard business development activity with no immediate negative financial implications.
Key Players & Entities
- AstraZeneca PLC (company) — Registrant
- CSPC (company) — Collaboration Partner
- 001-11960 (other) — SEC File Number
- 20250613 (date) — Filing Date
FAQ
What is the purpose of the collaboration between AstraZeneca and CSPC?
The filing states that the collaboration is to advance the development of innovative medicines.
When was this collaboration announced?
The filing was made on June 13, 2025, and the announcement pertains to this period.
What form was filed with the SEC?
A Form 6-K was filed with the SEC.
What is AstraZeneca's SEC file number?
AstraZeneca's SEC file number is 001-11960.
Where is AstraZeneca PLC headquartered?
AstraZeneca PLC is headquartered at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 13, 2025 regarding ASTRAZENECA PLC (AZN).